Blog

Patent claiming dose reduction for poor metabolizers affirmed at Federal Circuit.

Capital gains treatment is available only if the royalties are paid as consideration for all substantial rights to a patent.

Rejection of methyl homolog as prima facie obvious over old compound reversed under lead compound analysis.

Japanese patent laws allow applicants to extend patent protection an additional 18 months by following a simple filing sequence. 

Drug maker’s decision to list auto-injector patent was not unreasonable when FDA had declined to answer seven industry letters asking whether a drug delivery device patent could be listed in Orange Book.

Publication of clinical protocol on ClinicalTrials.gov might anticipate the underlying method of treatment, but not render the method of treatment obvious.

Prior art statement that drug was expected to work did not impart reasonable expectation of success because statement was based on post-hoc analyses of earlier studies.

Generic labeling induces doctors to practice patented method of treating subset of patients enrolled in pivotal clinical trial.

PTAB provides roadmap for rebutting routine optimization rejections.

Generic did not infringe formulation patent under doctrine of equivalents because it used an ingredient that patentee disclosed but did not claim.